Arcellx, Inc. (ACLX)

Arcellx Inc. shares have experienced a remarkable 75% surge in 2026, a significant jump directly linked to the company's impending acquisition, which will result in its delisting from the market. This development typically provides a premium for shareholders, a common outcome in M&A transactions. The President of Arcellx capitalized on this situation by selling $10 million worth of shares. While insider sales can sometimes be viewed negatively, in this context, it appears to be a logical consequence of the acquisition, which has already propelled the stock to elevated levels, making it soon untradable on public exchanges.

Markets Gazette reports that Arcellx (ACLX) shares experienced a modest uplift following the announcement of its acquisition by Gilead Sciences. The biopharmaceutical giant has agreed to purchase Arcellx for a substantial $7.8 billion, translating to $115 per share in cash. This strategic move underscores Gilead's significant investment in the burgeoning field of cancer therapy, particularly in Arcellx's innovative pipeline. For investors, this deal represents a clear positive catalyst for Arcellx, offering a premium valuation and immediate liquidity, while positioning Gilead for potential long-term growth in oncology.